An Integrated Microfluidic-SERS Platform Enables Sensitive Phenotyping of Serum Extracellular Vesicles in Early Stage Melanomas

集成微流体- SERS平台在早期黑素瘤中实现血清EVs的敏感表型分析

主讲人：陈星雅

Adv. Funct. Mater. 2022, 32, 2010296

Abstract：

Precise detection of early melanomas is essential as the stage of disease guides treatment options. One growing field that may facilitate the advancement of early melanoma detection, is achieved through profiling serum extracellular vesicles (EVs) using sensitive nanotechnology. As a proof of principle, using a detection platform that combines a microfluidic device and surfaceenhanced Raman spectroscopy (SERS), the expression profiles of 4 protein biomarkers in serum EVs (termed as “EV SERS signatures”) derived from 20 early stage melanoma patients (including in situ melanoma) and 21 healthy participants are multiplexed. Significantly higher signal intensities of selected protein biomarkers are observed in serum EVs from melanoma patients compared with healthy participants, with mean fold-changes ranging from 3.7 to 4.2. It is demonstrated that the EV SERS signatures can accurately separate melanoma patients and healthy individuals, with an area under the curve of 0.95. Thus, with further development, this ultra-sensitive detection platform, combined with the panel of melanoma-associated biomarkers, has the ability to differentiate early stage melanoma patients from healthy participants.

摘要：

早期黑色素瘤的精确检测是至关重要的，因为疾病的阶段指导治疗方案。一个可能促进早期黑色素瘤检测的发展领域，是通过使用敏感的纳米技术分析血清额外细胞囊泡(EVs)来实现的。作为原理证明，使用结合微流体装置和表面增强拉曼光谱(SERS)的检测平台，对来自20名早期黑色素瘤患者(包括原位黑色素瘤)和21名健康参与者的血清EVs中4种蛋白质生物标志物(称为“EV SERS特征”)的表达谱进行了多路复用。与健康参与者相比，在黑色素瘤患者的血清EVs中观察到的选定蛋白质生物标志物的信号强度显着更高，平均倍数变化范围为3.7至4.2。结果表明，EV SERS特征可以准确地区分黑色素瘤患者和健康个体，曲线下面积为0.95。因此，随着进一步的发展，这种超灵敏的检测平台，结合黑色素瘤相关的生物标志物，有能力区分早期黑色素瘤患者和健康参与者。